On the public citation graph

Efficacy and Safety of Immune Checkpoint Inhibitors Combined with TKIs for Recurrent or Metastatic Cervical Cancer with PIK3CA Mutation: A Secondary Analysis Based on Two Prospective Studies

0 signed · 23 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cac2.12183openalex-extracted
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges
inferredcites →https://doi.org/10.1002/cac2.12547openalex-extracted
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study
inferredcites →https://doi.org/10.1016/j.annonc.2021.04.009openalex-extracted
VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
inferredcites →https://doi.org/10.1016/j.tranon.2022.101516openalex-extracted
Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway
inferredcites →https://doi.org/10.1016/s0140-6736(17)31607-0openalex-extracted
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
inferredcites →https://doi.org/10.1016/s2214-109x(22)00501-0openalex-extracted
Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative
inferredcites →https://doi.org/10.1038/modpathol.2016.221openalex-extracted
Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer
inferredcites →https://doi.org/10.1038/s41467-018-03867-9openalex-extracted
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
inferredcites →https://doi.org/10.1038/s41591-024-03249-3openalex-extracted
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
inferredcites →https://doi.org/10.1080/14712598.2019.1646721openalex-extracted
Pembrolizumab for the treatment of cervical cancer
inferredcites →https://doi.org/10.1158/1535-7163.mct-14-0983openalex-extracted
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
inferredcites →https://doi.org/10.1186/s12920-022-01376-9openalex-extracted
Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China
inferredcites →https://doi.org/10.1186/s12943-019-0974-6openalex-extracted
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
inferredcites →https://doi.org/10.1186/s12943-022-01536-6openalex-extracted
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial
inferredcites →https://doi.org/10.1200/jco.18.01265openalex-extracted
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
inferredcites →https://doi.org/10.1200/jco.2017.74.5471openalex-extracted
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
inferredcites →https://doi.org/10.1200/jco.21.02091openalex-extracted
Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial
inferredcites →https://doi.org/10.3322/caac.70090openalex-extracted
inferredcites →https://doi.org/10.3389/fphar.2024.1405521openalex-extracted
Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway
inferredcites →https://doi.org/10.3390/ijms221910260openalex-extracted
Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
inferredcites →https://doi.org/10.3390/jcm10020220openalex-extracted
PI3KCA Mutations in Uterine Cervix Carcinoma
inferredcites →https://doi.org/10.21203/rs.3.rs-1324764/v1openalex-snapshot
Genomic landscape, immune characteristics and a prognostic mutation signature of cervical cancer in China
inferredcites →https://doi.org/10.3322/caac.21660openalex-snapshot
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.